Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumors
Abstract Background This study aims to explore the efficacy and safety of mirabegron in treating irritative symptoms induced by intravesical immunotherapy with Bacillus Calmette–Guerin (BCG) after transurethral resection of bladder tumors (TURBT). Methods A total of 160 patients subjected to TURBT w...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-11-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.4278 |
| _version_ | 1818730077547921408 |
|---|---|
| author | Kai Sun Di Wang Gang Wu Jian Ma Tianqi Wang Jitao Wu Jipeng Wang |
| author_facet | Kai Sun Di Wang Gang Wu Jian Ma Tianqi Wang Jitao Wu Jipeng Wang |
| author_sort | Kai Sun |
| collection | DOAJ |
| description | Abstract Background This study aims to explore the efficacy and safety of mirabegron in treating irritative symptoms induced by intravesical immunotherapy with Bacillus Calmette–Guerin (BCG) after transurethral resection of bladder tumors (TURBT). Methods A total of 160 patients subjected to TURBT was randomly divided into the mirabegron group and placebo group with 80 patients in each group. Then, the patients were administered 25 mg mirabegron or placebo daily, starting the first day after BCG infusion. The first BCG perfusion was conducted at least 2 weeks after TURBT. The 3‐day bladder diaries were completed in all patients, 1 day before BCG perfusion, and on the 1st, 6th, and 13th days after the first BCG perfusion. Overactive bladder symptom scores were completed 1 day before BCG perfusion, and on the 6th and 13th days after the first BCG perfusion. Results Symptom scores of bladder hyperactivity were significantly different between the two groups (p < 0.001). Also, the frequency of nocturia, pollakiuria, micturition urgency, urinary incontinence and was significantly lower in group 1 than that in group two (p < 0.05). Conclusion Our findings demonstrate that mirabegron is a valuable clinical drug for the management of irritative symptoms after TURBT with subsequent intravesical BCG perfusion. |
| first_indexed | 2024-12-17T22:56:03Z |
| format | Article |
| id | doaj.art-65fe3117c00d4761aa169209a96bfb60 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-12-17T22:56:03Z |
| publishDate | 2021-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-65fe3117c00d4761aa169209a96bfb602022-12-21T21:29:32ZengWileyCancer Medicine2045-76342021-11-0110217534754110.1002/cam4.4278Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumorsKai Sun0Di Wang1Gang Wu2Jian Ma3Tianqi Wang4Jitao Wu5Jipeng Wang6Department of Urology The Affiliated Yantai Yuhuangding Hospital of Qingdao University Yantai Shandong ChinaDepartment of Urology The Affiliated Yantai Yuhuangding Hospital of Qingdao University Yantai Shandong ChinaDepartment of Urology The Affiliated Yantai Yuhuangding Hospital of Qingdao University Yantai Shandong ChinaDepartment of Urology The Affiliated Yantai Yuhuangding Hospital of Qingdao University Yantai Shandong ChinaDepartment of Urology The Affiliated Yantai Yuhuangding Hospital of Qingdao University Yantai Shandong ChinaDepartment of Urology The Affiliated Yantai Yuhuangding Hospital of Qingdao University Yantai Shandong ChinaDepartment of Urology The Affiliated Yantai Yuhuangding Hospital of Qingdao University Yantai Shandong ChinaAbstract Background This study aims to explore the efficacy and safety of mirabegron in treating irritative symptoms induced by intravesical immunotherapy with Bacillus Calmette–Guerin (BCG) after transurethral resection of bladder tumors (TURBT). Methods A total of 160 patients subjected to TURBT was randomly divided into the mirabegron group and placebo group with 80 patients in each group. Then, the patients were administered 25 mg mirabegron or placebo daily, starting the first day after BCG infusion. The first BCG perfusion was conducted at least 2 weeks after TURBT. The 3‐day bladder diaries were completed in all patients, 1 day before BCG perfusion, and on the 1st, 6th, and 13th days after the first BCG perfusion. Overactive bladder symptom scores were completed 1 day before BCG perfusion, and on the 6th and 13th days after the first BCG perfusion. Results Symptom scores of bladder hyperactivity were significantly different between the two groups (p < 0.001). Also, the frequency of nocturia, pollakiuria, micturition urgency, urinary incontinence and was significantly lower in group 1 than that in group two (p < 0.05). Conclusion Our findings demonstrate that mirabegron is a valuable clinical drug for the management of irritative symptoms after TURBT with subsequent intravesical BCG perfusion.https://doi.org/10.1002/cam4.4278BCG immunotherapyirritative symptomsmirabegron |
| spellingShingle | Kai Sun Di Wang Gang Wu Jian Ma Tianqi Wang Jitao Wu Jipeng Wang Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumors Cancer Medicine BCG immunotherapy irritative symptoms mirabegron |
| title | Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumors |
| title_full | Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumors |
| title_fullStr | Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumors |
| title_full_unstemmed | Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumors |
| title_short | Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumors |
| title_sort | mirabegron improves the irritative symptoms caused by bcg immunotherapy after transurethral resection of bladder tumors |
| topic | BCG immunotherapy irritative symptoms mirabegron |
| url | https://doi.org/10.1002/cam4.4278 |
| work_keys_str_mv | AT kaisun mirabegronimprovestheirritativesymptomscausedbybcgimmunotherapyaftertransurethralresectionofbladdertumors AT diwang mirabegronimprovestheirritativesymptomscausedbybcgimmunotherapyaftertransurethralresectionofbladdertumors AT gangwu mirabegronimprovestheirritativesymptomscausedbybcgimmunotherapyaftertransurethralresectionofbladdertumors AT jianma mirabegronimprovestheirritativesymptomscausedbybcgimmunotherapyaftertransurethralresectionofbladdertumors AT tianqiwang mirabegronimprovestheirritativesymptomscausedbybcgimmunotherapyaftertransurethralresectionofbladdertumors AT jitaowu mirabegronimprovestheirritativesymptomscausedbybcgimmunotherapyaftertransurethralresectionofbladdertumors AT jipengwang mirabegronimprovestheirritativesymptomscausedbybcgimmunotherapyaftertransurethralresectionofbladdertumors |